Details of the Drug Pharmacogenomic Perturbation Atlas

Mercaptopurine Drug Info

6-mercaptopurine; Ismipur; Leukerin; Leupurin; Mercaleukim; Mercaleukin; Mercaptopurin; Mercaptopurina; Mercaptopurinum; Mercapurin; Merkaptopuryna; Mern; Purimethol; Purinethiol; Purinethol; Thiopurine; Leupu rin; Mercaptopurin [German]; Mercaptopurina Wellcome; Mercaptopurine anhydrous; Merkaptopuryna [Polish]; Puri Nethol; BW 57 323H; Glaxo Wellcome Brand of 6 Mercaptopurine; GlaxoSmithKline Brand of 6 Mercaptopurine; M0063; NCIMech_000025; PM6; Wellcome Brand of 6 Mercaptopurine; Glaxo Wellcome Brand of 6-Mercaptopurine; GlaxoSmithKline Brand of 6-Mercaptopurine; Mercaptopurina [INN-Spanish]; Mercaptopurine (INN); Mercaptopurine (VAN); Mercaptopurine (anhydrous); Mercaptopurinum [INN-Latin]; Puri-Nethol; Purineantimetabolite: inhibits nucleic acid replication; Purinethol (TN); U-4748; Wellcome Brand of 6-Mercaptopurine; AG-670/31547064; Purine-6-thiol; Leukerin, 99%-Carc; Purine-6(1H)-thione; Purinethol, 6-mercaptopurine, 6-MP, Mercaptopurine; 6 MP; 6 Mercaptopurine Monohydrate; 6 Thiohypoxanthine; 6 Thiopurine; 6-MERCAPTOPURINE MONOHYDRATE; 6-MP; 6-Mercaptopurin; 6-Merkaptopurin; 6-Merkaptopurin [Czech]; 6-Purinethiol; 6-Thiohypoxanthine; 6-Thiopurine; 6-Thioxopurine; Mercaptopurine (Purine analog)

Therapeutic Class

Anticancer Agents

Cross-matching ID

PubChem CID

667490

ChEBI ID

CHEMBL1425

CAS Number

CAS 50-44-2

TTD Drug ID

D09UZO

VARIDT Drug ID

DR00145

INTEDE Drug ID

DR1031

ACDINA Drug ID

D00399

General Information of Drug (ID: DMTM2IK)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Allograft rejection	2.13	0.00e+0	32/38 (84.21%)	PRF1;GZMB;CD40;...
Graft-versus-host disease	2.03	5.86e-3	32/42 (76.19%)	PRF1;GZMB;KLRD1;...
Viral protein interaction with cytokine and cytokine re...	2.03	3.91e-3	84/100 (84%)	CXCL13;CXCL12;CCR7;...
Autoimmune thyroid disease	2.00	5.86e-3	46/53 (86.79%)	PRF1;GZMB;CD40;...
Rheumatoid arthritis	1.93	7.04e-3	78/93 (83.87%)	CXCL12;VEGFA;MMP1;...
Steroid hormone biosynthesis	1.91	9.77e-3	43/61 (70.49%)	AKR1C3;AKR1C2;AKR1C1;...
Metabolism of xenobiotics by cytochrome P450	1.90	1.01e-2	49/77 (63.64%)	AKR1C1;ADH1B;ADH5;...
TNF signaling pathway	1.87	1.32e-2	103/112 (91.96%)	VCAM1;ATF4;AKT3;...
Type I diabetes mellitus	1.82	2.08e-2	38/43 (88.37%)	PRF1;GZMB;IFNG;...
Proximal tubule bicarbonate reclamation	1.80	2.35e-2	21/23 (91.3%)	CA2;PCK2;CA4;...
Mitophagy	1.77	2.77e-2	56/68 (82.35%)	ATF4;FIS1;SQSTM1;...
Ribosome	1.76	2.74e-2	113/158 (71.52%)	RSL24D1;RPL10A;RPL13A;...
AGE-RAGE signaling pathway in diabetic complications	1.75	2.62e-2	97/100 (97%)	VCAM1;VEGFA;AGTR1;...
Th1 and Th2 cell differentiation	1.72	3.35e-2	80/92 (86.96%)	IL2RB;LCK;RUNX3;...
Cytokine-cytokine receptor interaction	1.72	3.44e-2	246/295 (83.39%)	CXCL13;CXCL12;CCR7;...
Human T-cell leukemia virus 1 infection	1.69	4.10e-2	197/219 (89.95%)	CDKN2C;CDKN2A;ATF4;...
Transcriptional misregulation in cancer	1.69	3.93e-2	158/192 (82.29%)	PPARG;CDKN2C;DDIT3;...
Th17 cell differentiation	1.68	3.78e-2	95/107 (88.79%)	IL2RB;TGFBR2;LCK;...
N-Glycan biosynthesis	1.68	3.58e-2	38/50 (76%)	DDOST;B4GALT3;GANAB;...
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis	1.67	3.52e-2	20/26 (76.92%)	PIGV;PIGO;PIGP;...
Relaxin signaling pathway	1.67	3.35e-2	114/129 (88.37%)	ATF4;VEGFA;MMP1;...
Sulfur metabolism	1.65	4.26e-2	9/10 (90%)	ETHE1;TST;SELENBP1
Alanine, aspartate and glutamate metabolism	1.64	4.44e-2	27/37 (72.97%)	ASS1;ASNS;GLUD2;...
NF-kappa B signaling pathway	1.64	4.25e-2	90/104 (86.54%)	CXCL12;VCAM1;CCL19;...
Ether lipid metabolism	1.64	4.08e-2	32/49 (65.31%)	PLPP1;ENPP2;PLPP2;...
Longevity regulating pathway	1.63	4.42e-2	90/151 (59.6%)	PPARG;IRS2;ATF4;...
Nitrogen metabolism	1.62	4.39e-2	16/17 (94.12%)	CA2;CA4;GLUD2;...
Terpenoid backbone biosynthesis	-1.79	4.24e-2	18/22 (81.82%)	MVD;HMGCR;IDI1;...
Biosynthesis of unsaturated fatty acids	-1.99	1.99e-2	21/27 (77.78%)	HSD17B4;ELOVL6;ACAA1;...
Steroid biosynthesis	-2.20	0.00e+0	19/20 (95%)	LIPA;HSD17B7;FDFT1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
MCF7	CVCL_0031	Homo sapiens	0.01uM - 20uM	6H, 24H

MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 0.25uM	24H

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 20uM	6H, 24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.04uM - 10uM	24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
PC-3	CVCL_0035	Homo sapiens	0.01uM - 20uM	6H, 24H

VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.04uM - 10uM	24H